A5041226203- Immunotherapy and Immune Responses
- SARS-CoV-2 and COVID-19 Research
- vaccines and immunoinformatics approaches
- Monoclonal and Polyclonal Antibodies Research
- COVID-19 Clinical Research Studies
- Viral gastroenteritis research and epidemiology
- HIV Research and Treatment
- Animal Virus Infections Studies
- Immune Cell Function and Interaction
- Cellular transport and secretion
- Ubiquitin and proteasome pathways
- SARS-CoV-2 detection and testing
- Fungal and yeast genetics research
- Chemical Reactions and Isotopes
- Viral Infections and Outbreaks Research
- Lanthanide and Transition Metal Complexes
- Transgenic Plants and Applications
- Parvovirus B19 Infection Studies
- Protein Degradation and Inhibitors
- Amino Acid Enzymes and Metabolism
- Bacillus and Francisella bacterial research
- Virus-based gene therapy research
- Protein Structure and Dynamics
- Microbial Metabolic Engineering and Bioproduction
- Lipid Membrane Structure and Behavior
IrsiCaixa
2019-2025
Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol
2022-2023
Hospital Universitari Germans Trias i Pujol
2019
Commissariat à l'Énergie Atomique et aux Énergies Alternatives
2018
Institut de Recherches en Technologies et Sciences pour le Vivant
2018
Université Grenoble Alpes
2016-2018
Institut de Biologie Structurale
2018
CEA Grenoble
2018
Centre National de la Recherche Scientifique
2016
European Molecular Biology Laboratory
2013-2016
Abstract The protective effect of neutralizing antibodies in SARS-CoV-2 infected individuals is not yet well defined. To address this issue, we have analyzed the kinetics antibody responses and their association with disease severity. Between March May 2020, prospective KING study enrolled 72 COVID-19+ participants grouped according to infection was diagnosed by serological virological tests. Plasma were assessed against replicative virus pseudoviral particles. Multiple regression...
Protein-metabolite networks are central to biological systems, but incompletely understood. Here, we report a screen catalog protein-lipid interactions in yeast. We used arrays of 56 metabolites measure lipid-binding fingerprints 172 proteins, including 91 with predicted domains. identified 530 associations, the majority which novel. To show data set's value, studied further several novel sphingolipids, class conserved bioactive lipids an elusive mode action. Integration live-cell imaging...
Article25 May 2016Open Access Source DataTransparent process Structural evidence for Nap1-dependent H2A–H2B deposition and nucleosome assembly Carmen Aguilar-Gurrieri European Molecular Biology Laboratory, Grenoble, France Unit Virus Host–Cell Interactions, Univ. Grenoble Alpes–EMBL–CNRS, Search more papers by this author Amédé Larabi Vinesh Vinayachandran Center Eukaryotic Gene Regulation, Department of Biochemistry Biology, The Pennsylvania State University, University Park, PA, USA Nisha...
Antigen display on the surface of Virus-Like Particles (VLPs) improves immunogenicity compared to soluble proteins. We hypothesised that immune responses can be further improved by increasing antigen density VLPs. In this work, we report an HIV-1 Gag-based VLP platform engineered maximise presence surface. An gp41-derived protein (Min), including C-terminal part gp41 and transmembrane domain, was fused Gag. This resulted in high-density MinGag-VLPs. These VLPs demonstrated highly immunogenic...
Integration and down-regulation of cell growth differentiation signals rely on plasma membrane receptor endocytosis sorting towards either recycling vesicles or degradative lysosomes via multivesicular bodies (MVB). In this process, the endosomal complex-III required for transport (ESCRT-III) controls deformation scission triggering intraluminal vesicle (ILV) formation at early endosomes. Here, we show that ESCRT-III member CHMP1B can be ubiquitinated within a flexible loop known to undergo...
Abstract Background Neoantigens are patient- and tumor-specific peptides that arise from somatic mutations. They stand as promising targets for personalized therapeutic cancer vaccines. The identification process neoantigens has evolved with the use of next-generation sequencing technologies bioinformatic tools in tumor genomics. However, in-silico strategies selecting immunogenic still have very low accuracy rates, since they mainly focus on predicting peptide binding to Major...
<title>Abstract</title> <bold>Background: </bold>SARS-CoV-2 neutralizing antibodies may protect against symptomatic infection in immunized individuals. However, vaccine-induced antibody levels wane over time, reducing vaccine efficacy. The definition of the waning kinetics SARS-CoV-2 responses and potential impact sequential antigen encounters are still poorly defined. <bold>Methods:</bold> Plasma activity was determined longitudinally collected samples from infected, primo-vaccinated...
Neoantigens are tumor-specific antigens that mostly particular for each patient. Since the immune system is able to mount a specific response against these neoantigens, they promising tool development of therapeutic personalized cancer vaccines. must be presented T cells by antigen presenting (APC) in context MHC-I or MHC-II molecules. Therefore, strategy vaccine delivery may have major impact on magnitude and quality cell responses. Neoantigen-based vaccines frequently administered as pool...
The elicitation of cross-variant neutralizing antibodies against SARS-CoV-2 represents a major goal for current COVID-19 vaccine strategies. Additionally, natural infection may also contribute to broaden responses. To assess the contribution vaccines and infection, we cross-sectionally analyzed plasma neutralization titers six groups individuals, organized according number they received their history. Two doses had limited capacity generate cross-neutralizing Omicron variants concern (VOCs)...
Respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) vaccines have been long overdue. Structure-based vaccine design created a new momentum in the last decade, first RSV finally approved older adults pregnant individuals. These are based on recombinant stabilized pre-fusion F glycoproteins administered as soluble proteins. Multimeric antigenic display could markedly improve immunogenicity should be evaluated next generations of vaccines. Here we tested like particles-based...
Feline leukemia virus (FeLV) is one of the most prevalent infectious diseases in domestic cats. Although different commercial vaccines are available, none them provides full protection. Thus, efforts to design a more efficient vaccine needed. Our group has successfully engineered HIV-1 Gag-based VLPs that induce potent and functional immune response against transmembrane protein gp41. Here, we propose use this concept generate FeLV-Gag-based as novel strategy retrovirus. By analogy our...
Safe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are crucial to fight against the disease 2019 pandemic. Most based on a mutated version of Spike glycoprotein [K986P/V987P (S-2P)] with improved stability, yield immunogenicity. However, S-2P is still produced at low levels. Here, we describe V987H mutation that increases by two-fold production recombinant exposure receptor binding domain (RBD). S-V987H immunogenicity similar in mice golden Syrian...
The envelope glycoprotein (Env) of retroviruses, such as the Feline leukemia virus (FeLV), is main target neutralizing humoral response, and therefore, a promising vaccine candidate, despite its reported poor immunogenicity. incorporation mutations that stabilize analogous proteins from other viruses in their prefusion conformation (e.g., HIV Env, SARS-CoV-2 S, or RSV F glycoproteins) has improved capability to induce protective immune responses. Therefore, we have stabilized FeLV Env...
Most COVID-19 vaccines are based on the SARS-CoV-2 Spike glycoprotein (S) or their subunits. However, S shows some structural instability that limits its immunogenicity and production, hampering development of recombinant S-based vaccines. The introduction K986P V987P (S-2P) mutations increases production trimer, suggesting these two parameters related. Nevertheless, S-2P still molecular it is produced with low yield. Here we described a novel set identified by modeling located in S2 region...
Abstract Neoantigens are tumor-specific antigens that mostly particular for each patient. Since the immune system is able to mount a specific response against these neoantigens, they promising tool development of therapeutic personalized cancer vaccines. must be presented T cells by Antigen Presenting Cells (APC) in context MHC-I or MHC-II molecules. Therefore, strategy vaccine delivery may have major impact on magnitude and quality cell responses. Neoantigen vaccines frequently administered...
Abstract Safe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have been crucial to fight against the disease 2019 pandemic. Most are based on a mutated version of Spike glycoprotein [K986P/V987P (S-2P)] with improved stability, yield immunogenicity. However, S-2P is still produced at low levels. Here, we described novel V987H mutation that increases by two-fold production recombinant exposure receptor binding domain (RBD). S-V987H immunogenicity was...
Abstract Most COVID-19 vaccines are based on the SARS-CoV-2 Spike glycoprotein (S) or their subunits. However, S shows some structural instability that limits its immunogenicity and production, hampering development of recombinant S-based vaccines. The introduction K986P V987P (S-2P) mutations increases production trimer and, more importantly, immunogenicity, suggesting these two parameters related. S-2P still molecular it is produced with low yield. Thus, can be further optimized. Here we...
ABSTRACT Background Neoantigens are patient- and tumor-specific peptides that arise from somatic mutations. They stand as promising targets for personalized therapeutic cancer vaccines. The identification process neoantigens has evolved with the use of next-generation sequencing technologies bioinformatic tools in tumor genomics. However, silico strategies selecting immunogenic still have very low accuracy rates, since they mainly focus on predicting peptide binding to Major...